home / stock / prnb / prnb quote
Last: | $100.05 |
---|---|
Change Percent: | 0.1% |
Open: | $99.99 |
Close: | $100.05 |
High: | $100.37 |
Low: | $99.95 |
Volume: | 1,792,755 |
Last Trade Date Time: | 09/25/2020 04:55:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$100.05 | $99.99 | $100.05 | $100.37 | $99.95 | 1,792,755 | 09-25-2020 |
$99.95 | $99.9 | $99.95 | $100.01 | $99.9 | 468,023 | 09-24-2020 |
$99.95 | $100 | $99.95 | $100.04 | $99.95 | 502,551 | 09-23-2020 |
$100 | $99.97 | $100 | $100.08 | $99.96 | 501,353 | 09-22-2020 |
$100 | $100 | $100 | $100.16 | $99.92 | 950,268 | 09-21-2020 |
$100.27 | $100.05 | $100.27 | $100.39 | $99.95 | 1,974,410 | 09-18-2020 |
$100.05 | $99.94 | $100.05 | $100.18 | $99.9 | 538,905 | 09-17-2020 |
$99.99 | $100 | $99.99 | $100.16 | $99.96 | 920,895 | 09-16-2020 |
$99.96 | $99.99 | $99.96 | $100.03 | $99.91 | 268,763 | 09-15-2020 |
$100.02 | $100.08 | $100.02 | $100.12 | $99.88 | 338,190 | 09-14-2020 |
$100 | $99.97 | $100 | $100.04 | $99.86 | 701,240 | 09-11-2020 |
$99.85 | $100.03 | $99.85 | $100.05 | $99.81 | 533,230 | 09-10-2020 |
$99.97 | $100.02 | $99.97 | $100.07 | $99.94 | 504,450 | 09-09-2020 |
$99.98 | $99.94 | $99.98 | $100.07 | $99.88 | 682,109 | 09-08-2020 |
$100.07 | $100.03 | $100.07 | $100.2 | $99.76 | 837,308 | 09-07-2020 |
$100.07 | $100.03 | $100.07 | $100.2 | $99.76 | 837,308 | 09-04-2020 |
$100 | $99.9 | $100 | $100.03 | $99.78 | 892,295 | 09-03-2020 |
$99.99 | $100.02 | $99.99 | $100.04 | $99.93 | 572,652 | 09-02-2020 |
$100.01 | $99.98 | $100.01 | $100.1 | $99.87 | 2,100,523 | 09-01-2020 |
$100.01 | $100.81 | $100.01 | $100.81 | $99.96 | 914,981 | 08-31-2020 |
News, Short Squeeze, Breakout and More Instantly...
Principia Biopharma Inc. Company Name:
PRNB Stock Symbol:
NASDAQ Market:
Principia Biopharma Inc. Website:
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral inve...
NEW YORK, NY / ACCESSWIRE / September 19, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Maxim Integrated Products, Inc. (NASDAQ: MXIM...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to e...